Invention Grant
- Patent Title: Orally disintegrating tablets
-
Application No.: US16095090Application Date: 2017-04-20
-
Publication No.: US10729655B2Publication Date: 2020-08-04
- Inventor: Farhan Abdel Karim Mohammad Al Husban , Lars Håkan Christer Glad , Jenny Malin Christina Hallstein , Andrea Jane Moir , Michael Peter Thompson
- Applicant: AstraZeneca AB
- Applicant Address: SE Södertälje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Södertälje
- International Application: PCT/EP2017/059443 WO 20170420
- International Announcement: WO2017/182589 WO 20171026
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K9/20 ; A61J1/03 ; B65D75/32 ; A61K9/00 ; A61J3/10

Abstract:
The present invention relates to rapidly disintegrating oral dosage forms, more particularly to rapidly disintegrating tablets containing (1S,2S,3R,5S)-3-[7-{[1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3H-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5 5-(2-hydroxyethoxy)cyclopentane-1,2-diol and a disintegrating excipient. Blister packs suitable for use with the rapidly disintegrating oral dosage form are also disclosed.
Public/Granted literature
- US20190117577A1 ORALLY DISINTEGRATING TABLETS Public/Granted day:2019-04-25
Information query
IPC分类: